A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight

The GZPS master protocol will support two independent studies, J2A-MC-GZS1 and J2A-MC-GZS2. Each study will see how well and safely orforglipron works in adult female participants with stress urinary incontinence (SUI) who have obesity or overweight. SUI is leaking urine during movement or activity such as coughing or exercising. Participation in the study will last about 58 weeks from screening to safety follow-up.

NCT Number	NCT07202884
Lead Sponsor	Eli Lilly and Company
Conditions	Urinary Incontinence,Stress
Enrollment	1,000 participants
Start Date	2025-09-30
Primary Completion	2028-03 (estimated)
Study Completion	2028-03 (estimated)
Updated on ClinicalTrials.gov	2026-07-17